EMPIRI INC.
Empirical Precision Medicine
Transforming the Cancer Care Continuum
Scroll down to learn more
Why this matters
Empirical drug sensitivity data will speed up the discovery and development of innovative cancer therapies in the biopharma pipeline, enhancing treatment efficacy while minimizing expensive side effects and cutting overall healthcare costs.
​
At EMPIRI, we’re driven to revolutionize cancer care through real-time, patient-specific drug response insights. By evaluating how individual tumor tissues respond to targeted cancer therapies, we’re connecting cutting-edge biopharma research directly to patient needs, optimizing the development of effective treatments.
Our practical, clinically proven strategy is designed to work across all cancer types, unbound by genomic profiles or histologic classifications.
Services we provide
EMPIRI provides cutting-edge correlative study services for pharmaceutical research and clinical trials, using E-slice and single-cell sequencing technologies.
E-slice
​
We provide E-slice analysis using biopsy cores or surgical material to our select partners engaged in clinical trials in the TMC area and to our clients engaged in clinical development. We can provide early response data in time to make agile decisions on your trial enrollment.
​
Single-Cell Sequencing
We offer end-to-end single cell RNA sequencing service, from tissue dissociation to bioinformatics analysis. We decipher the complexity of each cancer ecosystem through droplet-based single cell RNA sequencing service, including immune profiling.
Collaborators and Clients
